Maze Therapeutics, Inc. (MAZE) Revenue History
Annual and quarterly revenue from 2022 to present
MAZE Revenue Over Time (2022–2025)
MAZE Revenue Growth History
0 of 1 years with positive growth- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- -100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $20.0M | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | -100.0% |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $2.5M | — |
| Q2 2024 | $165.0M | — |
MAZE Revenue Analysis (2022–2025)
Current Revenue & Growth
As of June 12, 2026, Maze Therapeutics, Inc. (MAZE) generated trailing twelve-month (TTM) revenue of $20.0 million. The most recent quarter (Q1 2026) recorded $20.0 million in revenue
Historical Growth Trajectory
MAZE's historical revenue data shows various trends over time. Maze Therapeutics, Inc.'s highest annual revenue of $167.5 million was recorded in 2024.
Peer Comparison
Compared to Healthcare sector peers — including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACMR (+19.7% YoY). Compare MAZE vs RARE →
MAZE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 MAZECurrent | $20M | - | - | - | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACMR | $901M | +19.7% | +41.9% | 12.1% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% |
MAZE Historical Revenue Data (2022–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-2,403,000 | - | $-142,899,000 | - |
| 2024 | $167.5M | - | $167.5M | 100.0% | $57.6M | 34.4% |
| 2023 | $0 | - | $0 | - | $-98,551,000 | - |
| 2022 | $0 | - | $0 | - | $-111,026,000 | - |
What if you invested $1,000 in MAZE back in 2022?
Total return with dividends reinvested · 4+ years of data
Calculate ReturnsHow much would $100/month in MAZE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs MAZE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationMAZE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowMAZE — Frequently Asked Questions
Quick answers to the most common questions about buying MAZE stock.
Is MAZE's revenue growth accelerating or slowing?
MAZE TTM revenue: $20M. YoY growth: N/A. 5-year CAGR: N/A.
What is MAZE's revenue history from 2022 to 2026?
Maze Therapeutics, Inc. (MAZE) revenue history spans 2022 to 2026. TTM revenue as of 2026 is $20M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is MAZE's long-term revenue growth rate (CAGR)?
Maze Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for MAZE.
Why does MAZE's quarterly revenue fluctuate?
MAZE quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Maze Therapeutics, Inc.'s revenue data from 2022 to 2026 shows full historical quarterly detail on this page.
How is MAZE's revenue distributed by segment?
MAZE reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does MAZE's revenue compare to industry peers?
Maze Therapeutics, Inc. (MAZE) with TTM revenue of $20M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.